Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
Chemistry World January 22, 2013 Andrew Turley	Flu vaccine without the eggs approved Flublok from US biotech Protein Sciences has become the first flu vaccine made using an insect virus to win marketing approval in the US.
The Motley Fool June 17, 2005 W.D. Crotty	Biotech's Apple Dumpling Gang Chiron has made a number of financial and planning mistakes in the production of its flu vaccine.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
The Motley Fool October 18, 2005 Rich Duprey	Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt.
The Motley Fool March 1, 2011 Brian Orelli	Uncle Sam Gives Novavax a Big Hand Up Cash is everything for a development-stage drugmaker.
The Motley Fool October 22, 2004 Rich Duprey	Chiron Reports Profit, But So What? The flu vaccine debacle overshadows the company's profits and earnings.
The Motley Fool December 10, 2004 Rich Duprey	Regulators Quarantine Chiron The FDA sends a warning letter on the heels of a suspension extension by British authorities. Whether shares of the pharmaceutical ultimately finish up or down, the one-two punch from U.S. and British authorities still points to an ailing company.
The Motley Fool December 13, 2011 Frank Vinluan	N.C. Novartis Site Is First Cell-Based Flu Vaccine Facility in the Country A Novartis' vaccine facility in North Carolina today became the first facility authorized by the FDA for emergency use during a pandemic.
BusinessWeek October 24, 2005 John Carey	New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work?
The Motley Fool August 20, 2007 Brian Orelli	Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign.
The Motley Fool October 29, 2004 Selena Maranjian	Flu Shots for the Elite The flu shot shortage offers some food for thought for investors. Here are some statistics showing the establishment has some problems with the priorities when it comes to the flu.
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
The Motley Fool January 26, 2005 Rich Duprey	Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
Chemistry World February 2006	Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development.
The Motley Fool June 12, 2009 Brian Orelli	Be Careful What You Wish For Do you have the stomach to profit from swine flu?
The Motley Fool January 14, 2005 Rich Duprey	Chiron's Mythical Flu Vaccine The vaccine maker does not know when or if it will be able to start manufacturing again. Investors should pay close attention.
Health October 2007 Sarah Clachar	Read this BEFORE you get a flu shot The flu vaccine may not be as good -- or as safe -- as you think.
The Motley Fool December 18, 2009 Brian Orelli	Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
The Motley Fool October 6, 2004 Rich Duprey	Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices.
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
BusinessWeek November 28, 2005 Kerry Capell	High-Velocity Vaccines PowderMed says its DNA technology would let it react quickly to a flu pandemic. A DNA flu vaccine would have huge advantages over traditional ones. But first, the company must prove in upcoming large-scale clinical trials that its vaccine can protect people from flu generally.
The Motley Fool August 21, 2009 Brian Orelli	Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend.
The Motley Fool July 25, 2007 Brian Orelli	Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
American Family Physician January 15, 2004	Influenza Vaccine What is influenza?... Who is at higher risk?... What is the flu vaccine?... Is the vaccine safe?... etc.
Popular Mechanics September 2006 Ben Harder	Seeking Immunity Pathogens like West Nile virus show no respect for borders. But a new class of vaccines may soon keep them in check.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool April 27, 2009 Brian Orelli	A Capitalist Pig's View of Swine Flu So you want to make money from the swine flu? Here's how to do so.
The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
Chemistry World July 24, 2009 Matt Wilkinson	Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared.
The Motley Fool July 28, 2005 Rich Duprey	Chiron's Tragic Quarter The biotech vaccine maker barely breaks even but boasts of its ability to meet full-year expectations.
The Motley Fool December 21, 2004 Rich Duprey	Chiron Requests a Second Thought Had the vaccine maker simply issued a press release with the incorrect information, it might be understandable, but investors might feel more at ease if it had gotten it right when it filed documents with the SEC.
American Family Physician October 1, 2004	Flu Vaccinations A general overview on what flu vaccines are and how they can help.
BusinessWeek February 9, 2004 Catherine Arnst	What You Need To Know About Avian Flu The current avian flu outbreak in Asia is the fifth since 1997 to infect humans. This has raised a red flag for infectious disease experts, who fear the strain could mutate and spark a devastating flu pandemic.
AskMen.com	1 Million Swine Flu Cases? Swine flu has infected as many as 1 million Americans, U.S. health officials said Thursday, adding that 6 percent or more of some urban populations are infected.
BusinessWeek February 4, 2010 Weintraub et al.	Swine Flu: The Pandemic That Wasn't Swine flu is waning, but the lessons of H1N1 could come in handy during a more serious epidemic.
AskMen.com Jacob Franek	Swine Flu: The Good, The Bad And The Ugly Here is a short list of what we do and don't know of swine flu.
National Defense June 2010 Austin Wright	Researchers Grow Vaccines on the Cheap A consortium backed by the Defense Advanced Research Projects Agency is trying to demonstrate that vaccines could more efficiently be grown inside tobacco plants, as opposed to chicken embryos.
The Motley Fool March 3, 2005 Rich Duprey	Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief.
The Motley Fool November 30, 2006 Brian Lawler	Happy (Sniffle) Holidays (Cough) It's flu season again, and the market for influenza vaccines is hot. Pharma investors, take note.
The Motley Fool September 16, 2009 Brian Orelli	Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration.
The Motley Fool March 16, 2006 Rich Duprey	Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about.
Chemistry World February 7, 2006 Jon Evans	Plant-Derived Drug Approved in US Dow AgroSciences has become the first biotech firm to gain US regulatory approval for a plant-derived drug. The company claims it will be able to manufacture many other vaccines, for animal and human diseases, using its plant-based production technology.
The Motley Fool October 5, 2004 Alyce Lomax	No Cheer for Chiron A U.K. regulatory body suspended its manufacturing license because of contamination. The company's misstep adds up to another rough flu season.